Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays

Volume: 486, Pages: 112837 - 112837
Published: Nov 1, 2020
Abstract
Coronavirus Disease 2019 (COVID-19) convalescent plasma (CCP) was approved by the FDA for use in severe cases of COVID-19 under an emergency Investigational New Drug (IND) protocol. Eligibility criteria for CCP donors includes documentation of evidence of COVID-19 either by viral RNA detection at the time of illness or positive SARS-CoV-2 IgG after recovery if diagnostic testing for COVID-19 was not performed at the time of illness. In addition...
Paper Details
Title
Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays
Published Date
Nov 1, 2020
Volume
486
Pages
112837 - 112837
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.